Humulin M3 (Insulin Human (Rdna))

Humulin M3 is indicated for the management of hyperglycemia in patients with diabetes.

• Type 1 diabetes mellitus as part of a basal‑bolus insulin regimen.
• Type 2 diabetes mellitus when diet, exercise, and oral agents do not achieve glycemic targets.
• Adjunct therapy during periods of increased insulin demand, such as illness or surgery.
• Use in combination with rapid‑acting insulin analogues for flexible dosing.
• Pediatric patients with type 1 diabetes, as approved by local regulatory authorities.

• Humulin M3 delivers recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, facilitating translocation of GLUT‑4 transporters to the cell membrane. This increases glucose uptake, suppresses hepatic gluconeogenesis, and promotes glycogen synthesis, thereby lowering circulating blood glucose concentrations. The effect persists for several hours, providing basal insulin coverage between meals and overnight.

Like all insulin preparations, Humulin M3 may cause adverse reactions, ranging from mild to severe.

Common

• Hypoglycemia, especially if meals are missed or dosing is excessive.
• Injection‑site pain, redness, or swelling.
• Lipohypertrophy at repeated injection sites.
• Weight gain associated with improved glycemic control.

Serious

• Severe allergic reactions, including anaphylaxis or urticaria.
• Hypokalemia or other electrolyte disturbances.
• Edema or heart failure exacerbation in susceptible patients.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.
• Acute pancreatitis.
• Vision changes due to rapid glucose shifts.

Healthcare providers should assess patient-specific factors before initiating Humulin M3 and monitor for safety concerns during therapy.

• Adjust dose in renal or hepatic impairment to avoid hypoglycemia.
• Use caution in patients with a history of severe hypoglycemia unawareness.
• Monitor blood glucose closely during pregnancy, illness, or changes in physical activity.
• Evaluate for allergic reactions at the first sign of rash, swelling, or breathing difficulty.
• Consider cardiovascular status, as rapid glucose shifts can affect heart function.
• Review concomitant medications that may mask hypoglycemia symptoms.

Humulin M3 can interact with other medicines, influencing glucose levels or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulin analogues without dose adjustment.
• Beta‑blockers that may blunt hypoglycemia warning signs.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, which increase hypoglycemia risk.
• Corticosteroids, which can raise blood glucose and require higher insulin doses.
• Diuretics, particularly thiazides, that may affect electrolyte balance.
• ACE inhibitors or ARBs, which may potentiate insulin sensitivity.